MacroGenics, Inc. develops novel biologics. The Company specializes in treatments for autoimmune disorders, cancer, and infectious diseases. MacroGenics serves the healthcare industry in the United States.

Current Report (Form 8-K | Period ending 2025-11-14)

Current Report (Form 8-K | Period ending 2025-11-12)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Macrogenics Inc (MGNX US)

Current Report (Form 8-K | Period ending 2025-11-14)

Current Report (Form 8-K | Period ending 2025-11-12)

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Current Report (Form 8-K | Period ending 2025-08-14)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)